Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 29 (2010), Issue 1, Pages 11-20
http://dx.doi.org/10.3233/DMA-2010-0721

Peptides in Low Molecular Weight Fraction of Serum Associated with Hepatocellular Carcinoma

Yanming An,1 Slavka Bekesova,1 Nathan Edwards,2 and Radoslav Goldman1,2

1Georgetown University, Department of Oncology, Lombardi Comprehensive Cancer Center, Washington, DC, USA
2Georgetown University, Department of Biochemistry and Molecular & Cellular Biology, Washington, DC, USA

Received 2 September 2010; Accepted 2 September 2010

Copyright © 2010 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The incidence of hepatocellular carcinoma (HCC) in the United States is increasing and the increase is projected to continue for several decades. The overall survival of HCC patients is poor and treatments are not effective in part because most of the diagnoses come at a late stage. The development of new markers for detection of HCC would significantly improve patient prognosis. This paper describes identification of candidate markers previously reported in our serologic study of an Egyptian population by quantitative comparison of matrix assisted laser desorption ionization time of flight (MALDI-TOF) mass spectra. To identify these marker candidates, we performed LC-MS/MS sequencing that identified nine native peptides associated with HCC, including two reported previously. Four truncations of N terminus of complement C3f and a fibrinopeptide increased in control sera; two complement C4α peptides, a zyxin peptide, and a coagulation factor XIII peptide increased in cancer patient sera. We have also identified increased biliverdin diglucuronide in the sera of cancer patients. These peptides could potentially serve as markers of HCC following additional validation studies; however, association of similar peptides with other diseases and cancers dictates a very cautious approach.